In vitro analysis of the epstein‐barr virus: Host balance in long‐term renal allograft recipients
- 15 January 1985
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 35 (1) , 43-49
- https://doi.org/10.1002/ijc.2910350108
Abstract
Four indlces of the EB virus carrier state, for which quantitative in vitro assays now exist, have been monitored in 55 renal allograft recipients under long‐term immunosuppression, each patient being tested on a single occasion. By comparison with parallel data from healthy control donors, the results indicate the extent to which virus replication in the throat and virusinfected B cells in the blood are increased as a result of immunosuppression; the concrodance between these two independent indices of the level of EB virus infection in vivo, first noted with healthy donors, was again observed within this large group of patients. Immunosuppression also leads to an impairment of virus‐specific memory T‐cell responsiveness and to an increase in anti‐viral antibody titres, but the results show that the level of virus infection prevailing in any one individual cannot be inferred directly from these immunological indices of the virus: host balance. In allograft patients on stable levels of immunosuppression, virus and host appear to establish a new equilibrium. Limited prospective studies suggest that the position of this new equilibrium depends critically upon the virus: host balance prevalling in the same individuals before immunosuppression began. This may be an important consideration in identifying patients for whom immunosppression may carry a particularly high risk of developing EB virus genome‐positive lymphoma.This publication has 26 references indexed in Scilit:
- A re‐examination of the epstein‐barr virus carrier state in healthy seropositive individualsInternational Journal of Cancer, 1985
- Studies on long‐term T‐cell‐mediated immunity to epstein‐barr virus in immunosuppressed renal allograft recipientsInternational Journal of Cancer, 1981
- Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein–Barr virus-induced B-cell linesNature, 1981
- LONG-TERM T-CELL-MEDIATED IMMUNITY TO EPSTEIN-BARR VIRUS IN RENAL-ALLOGRAFT RECIPIENTS RECEIVING CYCLOSPORIN AThe Lancet, 1981
- EPSTEIN BARR VIRUS NUCLEAR ANTIGEN POSITIVE LYMPHOMA AFTER CYCLOSPORIN A TREATMENT IN PATIENT WITH RENAL ALLOGRAFTThe Lancet, 1980
- CYCLOSPORIN A INITIALLY AS THE ONLY IMMUNOSUPPRESSANT IN 34 RECIPIENTS OF CADAVERIC ORGANS: 32 KIDNEYS, 2 PANCREASES, AND 2 LIVERSThe Lancet, 1979
- Long‐term T‐cell‐mediated immunity to epstein‐barr virus in man. I. Complete regression of virus‐induced transformation in cultures of seropositive donor leukocytesInternational Journal of Cancer, 1978
- Quantitative Evaluation of Epstein-Barr-Virus-Infected Mononuclear Peripheral Blood Leukocytes in Infectious MononucleosisNew England Journal of Medicine, 1977
- OROPHARYNGEAL EXCRETION OF EPSTEIN-BARR VIRUS BY RENAL TRANSPLANT RECIPIENTS AND OTHER PATIENTS TREATED WITH IMMUNOSUPPRESSIVE DRUGSThe Lancet, 1974
- ORAL EXCRETION OF EPSTEIN-BARR VIRUS BY HEALTHY SUBJECTS AND PATIENTS WITH INFECTIOUS MONONUCLEOSISThe Lancet, 1972